Use of dupilumab for localized bullous pemphigoid in an elderly indigenous woman residing in a Nunavik elders’ home: A case report
Abstract
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, primarily affecting older adults. Standard treatment includes high-potency topical or systemic corticosteroids, often with immunosuppressive steroid-sparing agents; however, these therapies can be difficult to administer and monitor in remote settings. We report a 70-year-old Indigenous woman from a remote northern community who presented with localized BP of the right thigh. Initial treatment with topical clobetasol and mupirocin resulted in partial improvement, but ongoing management was complicated by limited access to specialist care, residence in an assisted living facility, challenges with prolonged topical therapy, and the need for routine laboratory monitoring for many systemic agents. Dupilumab was initiated with a 600 mg loading dose followed by 300 mg every two weeks. After 3 months, the patient achieved complete clinical resolution without adverse events. This case highlights dupilumab as a practical, effective, non-immunosuppressive treatment option for BP in resource-limited settings.
Related
- Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin
- Deucravacitinib in concomitant psoriasis vulgaris and bullous pemphigoid: A case of sustained dual disease control
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- [Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
- Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges
BibTeX
@article{kanou2026dupilumab,
title = {{Use of dupilumab for localized bullous pemphigoid in an elderly indigenous woman residing in a Nunavik elders’ home: A case report}},
author = {Meghan Kanou MD and Vinesh Rao BS and Roy Khalaf MD and Ivan V. Litvinov MD, PhD, FRCPC},
journal = {SAGE Open Medical Case Reports},
year = {2026},
month = nov,
doi = {10.1177/2050313x261505826},
url = {https://doi.org/10.1177/2050313x261505826},
note = {CC BY},
}
RIS
TY - JOUR
TI - Use of dupilumab for localized bullous pemphigoid in an elderly indigenous woman residing in a Nunavik elders’ home: A case report
AU - Meghan Kanou MD
AU - Vinesh Rao BS
AU - Roy Khalaf MD
AU - Ivan V. Litvinov MD, PhD, FRCPC
PY - 2026
DA - 2026/11/04
JO - SAGE Open Medical Case Reports
DO - 10.1177/2050313x261505826
UR - https://doi.org/10.1177/2050313x261505826
AB - Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, primarily affecting older adults. Standard treatment includes high-potency topical or systemic corticosteroids, often with immunosuppressive steroid-sparing agents; however, these therapies can be difficult to administer and monitor in remote settings. We report a 70-year-old Indigenous woman from a remote northern community who presented with localized BP of the right thigh. Initial treatment with topical clobetasol and mupirocin resulted in partial improvement, but ongoing management was complicated by limited access to specialist care, residence in an assisted living facility, challenges with prolonged topical therapy, and the need for routine laboratory monitoring for many systemic agents. Dupilumab was initiated with a 600 mg loading dose followed by 300 mg every two weeks. After 3 months, the patient achieved complete clinical resolution without adverse events. This case highlights dupilumab as a practical, effective, non-immunosuppressive treatment option for BP in resource-limited settings.
SN - 2050-313X
ER -